Digipath’s GroSciences Moving Forward with Further Testing for its Patent Pending All-Natural, Plant-Derived Pesticide

BOULDER, CO, August 14, 2019 – Digipath, Inc. (OTCQB: DIGP), a service-oriented independent testing laboratory, data analytics and formulation firm focused on the developing cannabis and hemp markets, is pleased to announce that its GroSciences division has successfully completed preliminary validation testing on its patent pending all-natural, plant-derived pesticide, TERPO+ Broadspectrum. The product could potentially…

Letter to Shareholders

From the Office of the CEO April 13, 2015 Fellow DigiPath Shareholders: We expect to open our first cannabis analytical testing laboratory in just a few short weeks, and it looks like we’ll be one of the first labs to open in Nevada. As we help usher medicinal marijuana into the Silver State, I wanted…

Letter to Shareholders

From the Office of the CEO Fellow DigiPath Shareholders: This is a very exciting time to be involved in the digital pathology and cannabis industries, and as investors in DigiPath, Inc., you and I are stakeholders in both. As co-founder, and now CEO, of DigiPath, Inc., I am always looking to improve things—including how we…